Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2017 June;69(3) > Minerva Ginecologica 2017 June;69(3):269-85

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

Minerva Ginecologica 2017 June;69(3):269-85

DOI: 10.23736/S0026-4784.17.04043-6

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Current evidence and emerging drug therapies for overactive bladder

Matthew IZETT, Martino ZACCHE, Ganesh THIAGAMOORTHY, Dudley ROBINSON, Linda CARDOZO

Department of Urogynecology, King’s College Hospital NHS Foundation Trust, London, UK


PDF


Overactive bladder is a common symptom complex with health related quality of life impacts on the individual as well as utilizing health resources. Antimuscarinic therapy has been the mainstay of treatment and is well supported within the literature and guidelines. However, compliance is poor due to lack of efficacy and adverse events leading to the development of novel therapies. Mirabegron, the B3-adrenoreceptor agonist has emerged as an evidence-based alternative first or second line therapy. Two decades after its first clinical application for overactive bladder, intravesical botulinum toxin is now an important part of any clinician’s armamentarium for refractory cases. Despite these therapeutic options many patients find therapies ineffective or have adverse events. This has resulted in ongoing developments in the understanding of overactive bladder, potential new drugs and combination therapies, which this paper intends to review.


KEY WORDS: Urinary bladder, overactive - Urinary incontinence - Drug therapy

top of page